Sonelokimab - CAS 1414386-05-2

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody combining monovalent camelid-derived nanobodies targeting human interleukin (IL) -17A and IL-17F with human serum albumin VHHs, presenting it as a promising candidate for investigating plaque-type psoriasis treatments [1] [2].

Interleukin, MMP

Proteases/Proteasome, Immunology/Inflammation

1414386-05-2

-20°C

Ice Packs

Inhibitory Antibodies